BioCryst Pharmaceuticals, Inc. (BCRX) Covered Calls

BioCryst Pharmaceuticals, Inc. is a global biotechnology company specializing in oral small-molecule and protein therapeutics for rare diseases. In 2026, the company is transitioning into a multi-asset commercial leader following its acquisition of Astria Therapeutics and the expansion of its blockbuster HAE franchise, ORLADEYO, into the pediatric market.

You can sell covered calls on BioCryst Pharmaceuticals, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BCRX (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

BioCryst Pharmaceuticals, Inc. (BCRX) is a leader in the treatment of hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition. The company made history with ORLADEYO, the first oral, once-daily prophylactic treatment for HAE, which has significantly disrupted a market previously dominated by injectable therapies. BioCryst’s 2026 strategy focuses on "segmenting the HAE market" by offering a suite of oral and injectable options to meet diverse patient needs.

Core Business and Products

The company revenue engine is ORLADEYO (berotralstat), which is currently scaling toward blockbuster status. In early 2026, BioCryst expanded this franchise with the launch of ORLADEYO oral pellets for children aged 2 to 12. The company also markets RAPIVAB (peramivir), an intravenous flu treatment. Following the strategic divestiture of its European business in late 2025, BioCryst has streamlined its operations to focus on the high-margin U.S. market, which now accounts for over 90% of its total revenue.

Competitive Landscape

1. Halozyme Therapeutics, Inc. is a primary mid-cap biotech peer that competes for investor capital in the specialty drug delivery and rare disease space.
2. Alkermes plc competes in the specialty pharmaceutical market, offering a liquid and optionable benchmark for investors seeking exposure to commercial-stage biotech firms.
3. Amicus Therapeutics, Inc. is a direct rival in the rare disease category, specifically targeting high-value orphan drug indications with a similar commercial-scale infrastructure.
4. Takeda Pharmaceutical Company Limited (via Takhzyro) remains the heavyweight incumbent in the HAE market; its ADR (TAK) offers a highly liquid options market for those hedging rare-disease exposure.
5. Viking Therapeutics, Inc. is an emerging competitor in the metabolic and rare disease space, often trading in the same high-volatility clusters as BioCryst.

Strategic Outlook and Innovation

The strategic focus for BioCryst in 2026 is the integration of its $700 million acquisition of Astria Therapeutics. This deal added navenibart, a late-stage injectable HAE candidate, to the pipeline. For the 2026 fiscal year, the company has issued ORLADEYO revenue guidance of $625 million to $645 million. Management is prioritizing a 2026 non-GAAP operating profit as the company leverages its 4x return on sales and marketing spend to self-fund the Phase 3 development of its pipeline assets.

Innovation at BioCryst is currently centered on "Small-Molecule Protein Engineering." In 2026, the company is advancing BCX17725, a novel protein therapeutic for Netherton syndrome, into critical clinical phases. BioCryst is also utilizing a $400 million financing facility from Blackstone Life Sciences to accelerate its R&D programs. By combining its established oral commercial success with the newly acquired injectable tech from Astria, BioCryst aims to provide a comprehensive "one-stop-shop" for HAE patients through the 2030s.

Want more examples? BCPC Covered Calls | BCS Covered Calls